Analysts’ Weekly Ratings Changes for LifeStance Health Group (LFST)

LifeStance Health Group (NASDAQ: LFST) has recently received a number of price target changes and ratings updates:

• 11/6/2026 – LifeStance Health Group had its price target raised by Canaccord Genuity Group from $15.00 to $16.00. They now have a “buy” rating on the stock.
• 11/6/2026 – LifeStance Health Group had its price target raised by KeyCorp from $15.00 to $17.00. They now have an “overweight” rating on the stock.
• 11/5/2026 – LifeStance Health Group had its price target raised by BTIG Research from $18.00 to $20.00. They now have a “buy” rating on the stock.
• 11/4/2026 – LifeStance Health Group had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 10/5/2026 – LifeStance Health Group had its price target raised by KeyCorp from $13.00 to $15.00. They now have an “overweight” rating on the stock.

LifeStance Health Group Stock Performance

LFST opened at $14.37 on Thursday. LifeStance Health Group, Inc. has a 1-year low of $6.01 and a 1-year high of $15.66. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.44 and a quick ratio of 1.44. The firm has a market cap of $5.46 billion, a P/E ratio of 75.64 and a beta of 1.35. The company has a 50 day simple moving average of $12.74 and a two-hundred day simple moving average of $9.60.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. LifeStance Health Group had a net margin of 4.29% and a return on equity of 4.82%. The firm had revenue of $455.86 million during the quarter, compared to analyst estimates of $431.59 million. The company’s quarterly revenue was up 25.3% on a year-over-year basis. Equities analysts forecast that LifeStance Health Group, Inc. will post 0.18 earnings per share for the current fiscal year.

Insider Transactions at LifeStance Health Group

In other news, CTO Vukasin Paunovich sold 42,067 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total transaction of $541,402.29. Following the sale, the chief technology officer directly owned 205,379 shares of the company’s stock, valued at $2,643,227.73. This represents a 17.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.50% of the stock is currently owned by insiders.

LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance’s clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.